How blockbusters bend biopharma

Thursday, April 30, 2026 | 12:00 PM - 1:00 PM ET

Step back from any big pharma pipeline and the pattern is obvious: Blockbusters don't just define the top 15 — they bend the entire field.

The R&D alliances that keep biotechs alive don't get handed out evenly. They flow to companies breaking ground where pharma sees the biggest upside. That shapes who gets funded, what gets built, and who gets left behind. John Carroll will be digging into this angle along with other key trends affecting late-stage drug development.

Carroll's annual R&D 15 report is the clearest picture available of where the industry's biggest players are placing their bets — and where they're quietly pulling back. He's bringing it off the page, joined by some of the most senior R&D minds in the business. Don't miss out.

SPONSORED BY

Sponsorship opportunities are available.
Contact Meg at mestacio@endpointsnews.com to learn how you can support Endpoints' R&D 15 2026.

Questions about registration? Contact our support team.